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Dr Hartzell V. Schaff (Rochester, Minn). Thank you, Dr Miller,
DrKron. I want to congratulate DrCohen on a beautiful presentation.
He and his colleagues have provided important information on the
10-year follow-up of a comparative study of the stented and stentless
valves. He has shown no difference in the mass regression when
comparing the 2 groups. There is no real difference in hemodynam-
ics, perhaps a 3-mm gradient, which was statistically significant but
appears not to be clinically important. The most important feature is
that there does not appear to be a difference in clinical outcome.
The limitations of the study are clear. It is a small group of pa-
tients, but I think that the strengths should be emphasized. If there
is anyone from the US Food and Drug Administration here or if any
of our colleagues consult for the Food and Drug Administration,
this is really a model for how valve studies should be performed.
It is randomized, and importantly, the patients are stratified accord-
ing to annular diameter and not to labeled valve size.
I have a few questions. Dr Miller asked that we take these in or-
der. You found no difference in mass regression between the
stented and stentless valves, but did you do any analysis that looks
at the predictors of mass regression in the overall group? For exam-
ple, is there any subgroup that might benefit from this small 3-mm
gradient difference, such as those with more severe degrees of hy-
pertrophy or hypertension?
Dr Cohen. We actually did, and although there was a slight
beneficial trend in female subjects, in general, the numbers were
too small to enable any conclusive statements.
Dr Schaff. And you found that the regurgitant orifice areas in the
stentless group improved over time, but that was at the expense of
an increased degree of aortic regurgitation in that group. Did you
analyze valve areas in patients who had no aortic regurgitation at
the end of follow-up?
Dr Cohen. I would say specifically no. However, we did ex-
clude patients who had either moderate to moderate–severe aortic
regurgitation. Therefore all of the patients we included in the echo-
cardiographic follow-up had little or no residual AI. Those who didrdiovascular Surgery c Volume 139, Number 4 857
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nate the findings with patients who had some evidence of valve dys-
function or valve deterioration.
Dr Schaff. It is also an interesting study in one final regard, and
that is that it seems the most important findings are not the differ-
ences that are statistically significant but perhaps a nonsignificant
difference that is clinically important; that is, the appearance that
there is decreased durability of the stentless valves. The stentless
valves were introduced with the idea that the flexibility might im-
prove long-term durability. Can you comment on why you found
the opposite?
Thank you.
Dr Cohen. Thank you, Dr Schaff. One of the things we did look
at through MRI assessment was the flexibility of the aortic annulus
after stented versus stentless valve implantation. The feeling was
that when we initially implanted these valves there would be
more flexibility in patients receiving stentless valves and that this
would translate to improved durability. In fact, we were not able
to find any differences or changes in the configuration of the annu-
lus by MRI assessment.
As to why the patients receiving stentless valves had poor dura-
bility over time, there are 2 reasons. First, when the Toronto stent-
less porcine valve was initially introduced, there was no
anticalcification treatment. Therefore, we found that our patients
with stentless valves tended to have calcification of the leaflets
somewhat earlier than those receiving pericardial valves. The other
issue is that when we initially implanted the stentless valve, we
really did not think much about the interrelation of a subcoronary
implant with the aortic root. Obviously what we found, especially
in patients with bicuspid aortic valves who were prone to aortic root
dilatation over time, was that displacement of the commissures of
the stentless valve caused eventual leaflet tears or what we define
in our study as nonstructural valve dysfunctions. Those 2 issues
were the ones that I think contributed to most of the failures in
the patients receiving stentless valves.
Dr. D. Craig Miller (Stanford, Calif). Gideon, I might have
missed it, but for which primary end points is this study adequately
powered statistically to support this conclusion of no difference? Is
there a chance of a type 2 or b error here?
Dr Cohen. That is an excellent question. We were underpow-
ered to make any definitive conclusions with respect to clinical out-
comes. There is no question about that. Our primary and secondary
outcomes were LV mass regression and functional outcome based
on the DASI score, and we were adequately powered for those 2
outcomes.
Dr Joseph E. Bavaria (Philadelphia, Pa). I would amplify what
Dr Schaff said about the beauty of this prospective randomized
study. It was very nicely done and produced great 9-year data.
We will learn a lot from it.
My question really is regarding the same thing Dr Schaff talked
about, which is structural valve deterioration for this subcohort you858 The Journal of Thoracic and Cardiovascular Surghave presented. There are fairly reasonable data coming out on the
Freestyle root, as well as the full root Toronto valve, that if you per-
form full root operations, you do not get these structural valve de-
teriorations that you see in your study. Therefore I would like for
you to comment on the controversy regarding full root versus sub-
coronary stentless implantation and as it pertains to early and mid-
term structural valve deterioration.
Dr Cohen. Thank you very much. That is an excellent question
once again. There has been a lot of talk advocating full root replace-
ments for isolated aortic valve disease, and there have been some
series that have reported excellent outcomes with equal morbidity
and mortality to that of just plain old aortic valve replacement.
To be honest with you, I am not sure we should be advocating
full root replacement for isolated aortic valve disease. To me, that
is tantamount to recommending total colectomy for acute appendi-
citis. It does not make much sense. Although there are certain
groups that I am sure can achieve excellent outcomes, I am not
sure that the average surgeon, myself included, is willing to submit
his patients, most of whom are now 70 to 80 years of age or older, to
full root replacement for isolated aortic valve disease, especially in
the absence of definitive clinical evidence of benefit with stentless
valves and a full root replacement.
Dr Thoralf Sundt (Rochester, Minn). Because you are looking
at LV mass regression, and maybe you mentioned this and I missed
it, a lot of your patients have hypertension, and we are well aware
that hypertension can have as profound an effect on LVmass as the
valve itself. How did you go about evaluating the adequacy of an-
tihypertensive therapy in the 2 groups, are you sure that they were
similar, so on and so forth?
Thank you very much.
Dr Cohen. We initially stratified our study by annular diameter,
coronary disease, and surgeon. We did not stratify by hypertension
because it is very difficult to diagnose or to definitively say that a pa-
tient has hypertension preoperatively because high blood pressure
might be a physiologic response to aortic stenosis. Therefore we
did not stratify ahead of time, and we hoped—and in fact it was
the case because of the randomized nature of this study—that there
were an equal number of hypertensive patients in both groups; ac-
tually, they were identical percentages.
I think that there is no question that hypertension—ongoing
hypertension—might have had an effect; however, for all of our
patients who were followed, we confirmed adequate control of
hypertension postoperatively through frequent visits and close
follow-up with cardiologists.
Dr Miller. I have one little bit of unsolicited advice worth ex-
actly zero pesos. That MRI on the right, I will bet you a 6-pack
that was a bicuspid valve and you should have replaced the tubular
segment of the ascending aorta.
Dr Cohen. You are probably right. Thanks.
DrMiller. Left a little guppy aneurysm behind in the context of
bicuspid aortic valve disease.ery c April 2010
Cohen et al Acquired Cardiovascular Disease
A
C
DAppendix 1. Echocardiographic parameters and
calculations
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where CSALVOT is defined as left ventricular outflow tract
(LVOT) cross-sectional area (pR2/4) in square centimeters
obtained from 2Dmeasurement of LVOT diameter; TVILVOT
is defined as the time velocity integral of forward blood flow
in centimeters derived from pulsed-wave (PW) Doppler
scanning in the LVOT; and TVIAO is defined as the time ve-
locity integral of forward blood flow in centimeters derived
from transvalvular continuous-wave (CW) Doppler scan-
ning.Cardiac output
Cardiac output (CO) is calculated by using the following for-
mula:
CO ¼ ðTVILVOT3CSALOVTÞ x HRðin L=minÞ;
where TVILVOT is defined as the time velocity integral of for-
ward blood flow in centimeters derived from PW Doppler
scanning in the LVOT; CSALVOT is defined as the LVOT
cross-sectional area (pR2/4) in square centimeters obtained
from 2Dmeasurement of LVOT diameter; andHR is defined
as heart rate in beats per minute.Peak pressure gradient
Peak velocities obtained from PW and CWDoppler scanning are






for an aortic valve peak systolic
pressure gradient in millimeters of mercury;
where V2 is defined as peak transvalvular velocity in meters
per second asmeasured with CWDoppler scanning and V1 is
defined as peak velocity in the LVOT in meters per second,
as measured with PW Doppler scanning.Mean pressure gradient
Mean transvalvular pressure gradient is calculated by subtrac-
tion of the mean pressure proximal to the aortic valve from theThe Journal of Thoracic and Camean distal pressure. Mean pressures are obtained by means of
planimetry of the Doppler spectral envelope.
DPMEAN ¼ ðP2P1Þ;mean transvalvular pressure gradient
in millimeters of mercury;
where P2 is defined as mean distal pressure in millimeters of
mercury, as measured with CW Doppler scanning, and P1 is
defined as mean pressure in the LVOT in millimeters of
mercury, as measured with PW Doppler scanning.
LV mass
LV mass ¼ 0:831:043ðLVIDdþPWTdÞ3ðLVIDdÞ3
þ0:6g;
where LVIDd is defined as LV internal dimension at end-
diastole in centimeters; IVSd is defined as interventricular
septal thickness at end-diastole in centimeters; and PWTd
is defined as posterior wall thickness at end-diastole in
centimeters.
*This formula for LV mass is based on the volume-corrected
ASE cube method.10
LV function
The percentage of fractional shortening, when derived from
M-mode measurements, is based on minor axis shortening and
assumes the ventricle contracts symmetrically.
%DD ¼ ðLVIDdLVIDSÞ=LVIDd3100%;
where LVIDd is defined as LV internal dimension at end-
diastole in centimeters and LVIDs is defined as LV internal
dimension at end-systole in centimeters.
Velocity of circumferential fiber shortening, when derived from
M-mode measurements, represents the velocity of fiber shortening
in the minor axis rather than in the whole circumference.
Vcf ¼ ðLVIDdLVIDsÞ=LVIDd3LVETÞin circumferences
per second
where LVIDd is defined as LV internal dimension at end-
diastole in centimeters; LVIDs is defined as LV internal
dimension at end-systole in centimeters; and LVET is
defined as LV ejection time in milliseconds measured
from the onset to the end of systolic flow.rdiovascular Surgery c Volume 139, Number 4 859
